Skip to main content
KNSA
NASDAQ Life Sciences

Kiniksa Pharmaceuticals Reports Strong 2025 ARCALYST Revenue and Positive 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41.12
Mkt Cap
$3.117B
52W Low
$17.82
52W High
$44.42
52W Position info
131% above low
Off High info
7.4% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

KNSA has more than doubled off its 52-week low of $17.82 on elevated volume (1.9× avg).

Summary

Kiniksa Pharmaceuticals reported strong unaudited 2025 ARCALYST revenue with 62% year-over-year growth and issued positive 2026 revenue guidance. The company also highlighted a robust cash position and pipeline advancements.


Key Events · Earnings and Guidance · KNSA

  • Strong 2025 ARCALYST Revenue

    Unaudited net product revenue for ARCALYST reached $677.5 million for the full year 2025, representing approximately 62% year-over-year growth.

  • Positive 2026 Revenue Guidance

    Kiniksa expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million.

  • Robust Financial Position

    As of December 31, 2025, the company had $414.1 million in cash, cash equivalents, and short-term investments with no debt, and expects to remain cash flow positive annually.

  • Pipeline Advancement

    Phase 2 data for KPL-387 in recurrent pericarditis is expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is planned to initiate by year-end 2026.


Analysis · KNSA · Life Sciences

Kiniksa Pharmaceuticals announced robust unaudited full-year 2025 net product revenue for ARCALYST, demonstrating significant year-over-year growth. The company also provided strong revenue guidance for 2026, indicating continued commercial momentum for its key product. Furthermore, Kiniksa reported a healthy cash position with no debt and expects to remain cash flow positive, providing financial stability to advance its pipeline. These updates, combined with progress on its KPL-387 and KPL-1161 programs, suggest a positive outlook for the company's financial performance and future growth catalysts.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KNSA was trading at $41.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $17.82 to $44.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KNSA - Latest Insights

KNSA
Oct 30, 2026, 6:20 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $92.15
Real-time Price: $96.40 info
Change: +$4.25 (+5%) info
Market Cap: $7.524B info
KNSA
Oct 27, 2026, 4:36 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $89.40
Real-time Price: $96.40 info
Change: +$7.00 (+8%) info
Market Cap: $7.524B info
KNSA
Oct 27, 2026, 11:43 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.37
Real-time Price: $96.40 info
Change: +$9.03 (+10%) info
Market Cap: $7.524B info
KNSA
Oct 27, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $74.99
Real-time Price: $96.40 info
Change: +$21.41 (+29%) info
Market Cap: $7.524B info
KNSA
Jul 28, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $79.95
Real-time Price: $96.40 info
Change: +$16.45 (+21%) info
Market Cap: $7.524B info